Who is the CEO of Daebongls?

According to the DART company overview, Daebongls' representative director is 박종호, 박진오 (name as registered in Korean). The company was founded on 1986-07-08.

Where is Daebongls listed?

Daebongls trades on the Korea Exchange KOSDAQ market under the ticker 078140. Its fiscal year ends in December.

Does Daebongls pay a dividend?

Yes. For fiscal 2025, Daebongls paid a cash dividend of ₩50 per common share, a 0.6% yield as stated in its annual report, with a payout ratio of 12.0%. The prior year's dividend was ₩50.

Which companies are in the same industry as Daebongls?

Under the Korean Standard Industrial Classification recorded on DART, Daebongls is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Daewoong Pharma and GC Biopharma.

Daebongls KRX:078140KOSDAQ

대봉엘에스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days0

Articles tracked37since Sep 11

In Q2 2026, Daebongls reported revenue of ₩33.7bn, up 27.2% year on year, and operating profit of ₩3.7bn. Daebongls (대봉엘에스) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Nov 2 with 1 article. The most common catalyst was earnings (1).

Daebongls quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩33.7bn	+27.2%	₩3.7bn margin 10.9%	₩1.8bn
Q1 2026	₩29.1bn	+12.0%	₩2.0bn margin 6.9%	₩584m
Q4 2025 derived	₩24.8bn	+7.3%	₩598m margin 2.4%	−₩1.2bn
Q3 2025	₩24.8bn	+2.5%	₩768m margin 3.1%	₩1.6bn
Q2 2025	₩26.4bn	+12.2%	₩2.4bn margin 8.9%	₩7.8bn
Q1 2025	₩25.9bn	+12.8%	₩3.6bn margin 13.9%	₩3.7bn
Q4 2024 derived	₩23.2bn	+3.6%	₩1.5bn margin 6.7%	−₩429m
Q3 2024	₩24.2bn	+10.4%	₩3.2bn margin 13.0%	₩6.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Daebongls top stories 2 weeks, by number of outlets

1
Daebong L.S., expecting 80% increase in operating profit this year on growth in cosmetic materials
1 outlets · 1 articlesFirst report Nov 9 13:14 메디파나뉴스Earnings
2
Daebong LS, cosmetics materials driving and pharmaceuticals pushing growth
1 outlets · 1 articlesFirst report Nov 2 08:36 파이낸셜뉴스
3
J&P Medi links with biotech firms including Daebong L&S to expand commercialization cooperation
1 outlets · 1 articlesFirst report Nov 3 10:16 한스경제

Latest Daebongls news Korean headlines

Nov 913:14

MajorDaebong L.S., expecting 80% increase in operating profit this year on growth in cosmetic materials
메디파나뉴스Earnings
Nov 310:16

J&P Medi links with biotech firms including Daebong L&S to expand commercialization cooperation
한스경제
Nov 208:36

Daebong LS, cosmetics materials driving and pharmaceuticals pushing growth
파이낸셜뉴스
Oct 3016:17

Daebong LS eyes 2027 results surge riding K-beauty wave into pharmaceuticals
한스경제
Oct 3015:26

Daebong LS cosmetic ingredient sales double in three years, Daishin Securities reports
뉴스핌Analyst reportDaishin Securities
Oct 3014:22

MajorDaebong LS increases cosmetics material sales, pursuing pharmaceutical technology transfer
브릿지경제Licensing deal
Oct 3014:09
Dabong LS eyes cosmetic ingredient growth with pharmaceutical business, targeting monetization by 2027
메디파나뉴스
1 more on this story · 1 outlets
- Daebong LS sees pharmaceutical monetization potential amid cosmetic ingredient growth서울경제 · Oct 30 15:07
Oct 1911:14

Growth Research: Daebong E&L, T&L, Xenics boost overseas sales for growth opportunity
한스경제Genic T&L
Oct 1308:05

MajorSearch e-stock: Daebong LS backed by co-developed materials with Cosmax and Kolmar Korea, stock momentum ahead?
데일리인베스트PartnershipKolmar Korea Cosmax
Oct 907:00

MajorDaebong LS subsidiary P&K commercializes AI clinical data platform...second quarter revenue generation
이투데이Clinical trial
Oct 811:00

Daebong LS develops culture medium raw materials with CJ...pursuing medical device finished products
메디파나뉴스
Oct 810:46

Korea IR Council: Daebong LS cosmetic ingredients show high growth...revaluation of valuation expected
뉴시스경제
Oct 810:41

Daebong LS forecast for record operating profit...expectations for cosmetic ingredient commercialization
한스경제
Oct 810:17

Korea IR Council: Daebong LS cosmetic ingredients show high growth...operating profit expected to surge 80%
뉴스핌Earnings
Oct 622:46

Discarded carrot leaves become premium skin treatment...Daebong LS proves K-beauty technology at global cosmetics conference
지이코노미
Oct 610:30
Daebong LS presents four papers on cosmetic ingredient and formulation research at IFSCC
메디파나뉴스
1 more on this story · 1 outlets
- Daebong LS unveils cosmetic ingredient research한스경제 · Oct 6 16:51
Oct 609:53
Daebong LS presents four papers on ingredient, delivery, and formulation research at IFSCC 2026
더케이뷰티사이언스
1 more on this story · 1 outlets
- Daebong LS proves cosmetic ingredient and formulation research capabilities at IFSCC 2026보건신문 · Oct 6 15:01
Oct 520:23

Daebong LS and Incheon National University receive Minister of Education award for red beet exosome university-industry cooperation
더케이뷰티사이언스
Oct 519:59

Daebong LS commercializes Euglena beta-glucan raw materials
더케이뷰티사이언스
Oct 121:36

Daebong LS receives Minister of Education commendation for converting university technology into market products through university-industry cooperation
지이코노미
Oct 111:07

Daebong LS achieves consecutive successes in university-industry cooperation with Incheon National University, Pusan National University and others
파이낸셜뉴스
Oct 109:44
Daebong LS wins Minister of Education award for red beet exosome university-industry cooperation
메디파나뉴스
1 more on this story · 1 outlets
- Daebong LS receives Minister of Education award for research cooperation with Incheon National University on red beet exosomes보건신문 · Oct 1 13:45
Oct 108:27

Daebong LS wins Minister of Education award at university-industry cooperation excellence competition
뉴시스경제
Sep 3023:16

Daebong LS achieves localization of next-generation cosmetic ingredients with marine microorganisms for skin barrier protection
지이코노미
Sep 3014:51

Incheon National University and Daebong LS receive Minister of Education award for joint research on plant-derived exosomes
경기일보Partnership
Sep 3010:27

Daebong LS commercializes cosmetic raw materials derived from Euglena
메디파나뉴스
Sep 3010:15
Daebong LS develops and commercializes high-function cosmetic ingredients based on marine microalgae
MTN
1 more on this story · 1 outlets
- Daebong LS develops and commercializes high-function cosmetic ingredients based on marine microalgae머니투데이 · Sep 30 10:21
Sep 2908:10

Daebong LS expands beyond K-beauty into haircare...US exports drive earnings
핀포인트뉴스
Sep 2817:18

Daebong LS stock rises 8.27% to 7,990 won in after-market trading on Sept. 28
중앙이코노미뉴스
Sep 2811:40

MajorDaebong LS prepares to supply GLP-1 raw materials...pursuing technology transfer
메디파나뉴스Licensing deal

Articles per day 2 weeks

Company profile

CEO: 박종호, 박진오
Industry: Pharmaceuticals
Founded: 1986-07-08
Fiscal year-end: December
Head office: 인천광역시 연수구
Website: daebongls.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Daebongls dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩50	0.6%	12.0%
FY2024	₩50	0.4%	15.7%
FY2023	₩50	0.6%	20.4%

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩37.8bn	641
Daewoong Pharma	₩71.3bn	475
GC Biopharma	–	455
Yuhan	–	410
Chong Kun Dang Pharmaceutical	–	176
HK inno.N	–	176
Jeil Pharmaceutical	–	149
DongKookPharmaceutical	–	146

Compare Daebongls side by side with these companies

Daebongls DART filings

Sep 2113:22

Corporate briefing (IR) held
Other

Catalysts 2 weeks

Earnings1

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Related themes

K-beauty2

Daebongls FAQ

Who is the CEO of Daebongls?: According to the DART company overview, Daebongls' representative director is 박종호, 박진오 (name as registered in Korean). The company was founded on 1986-07-08.
Where is Daebongls listed?: Daebongls trades on the Korea Exchange KOSDAQ market under the ticker 078140. Its fiscal year ends in December.
What were Daebongls' latest quarterly results?: In Q2 2026, Daebongls reported revenue of ₩33.7bn, up 27.2% year on year, and operating profit of ₩3.7bn. Figures come from reports filed on DART.
Does Daebongls pay a dividend?: Yes. For fiscal 2025, Daebongls paid a cash dividend of ₩50 per common share, a 0.6% yield as stated in its annual report, with a payout ratio of 12.0%. The prior year's dividend was ₩50.
Which companies are in the same industry as Daebongls?: Under the Korean Standard Industrial Classification recorded on DART, Daebongls is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Daewoong Pharma and GC Biopharma.